Athlete's Foot Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Athlete's Foot Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034


The 7 major athlete's foot markets reached a value of US$ 675.3 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 860.5 Million by 2034, exhibiting a growth rate (CAGR) of 2.23% during 2024-2034.

The athlete's foot market has been comprehensively analyzed in IMARC's new report titled "Athlete's Foot Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Athlete's foot, which is also referred to as tinea pedis, is a fungal infection that affects the skin on the feet, particularly between the toes. The symptoms of the disorder can vary from person to person but typically include itching, burning, and stinging on the impacted area. The skin may also become scaly, dry, and flaky, and blisters or ulcers may develop in severe cases. Additionally, the infection can spread to other areas of the feet, as well as to the toenails, causing them to become thick, brittle, and discolored. In some instances, the disease may also cause a foul odor or a rash on the foot. Diagnosing the ailment usually involves a physical examination of the affected area, as well as a review of medical history and symptoms. In certain cases, a skin culture is taken to identify the specific type of fungus causing the infection. This entails taking a small sample of the affected skin and sending it to a laboratory for analysis. Various other tests, such as a skin scraping or a Wood's lamp examination, are also used to help diagnose the infection.

The increasing cases of fungal infections caused by exposure to warm and humid environments or poor foot hygiene are primarily driving the athlete's foot market. In addition to this, the rising prevalence of numerous associated risk factors, including weakened immune system, wearing tight-fitting footwear, genetic predisposition, etc., is also bolstering the market growth. Furthermore, the widespread adoption of antifungal powders, such as talcum or zeasorb, to keep the feet dry and prevent the formation of fungus is acting as another significant growth-inducing factor. Apart from this, the escalating demand for over-the-counter pain relievers, including ibuprofen or acetaminophen, for relieving pain and discomfort associated with athlete's foot is further creating a positive outlook for the market. Moreover, the inflating utilization of probiotics, since they aid in reducing fungal infections by promoting a healthy balance of microorganisms on the skin, is also augmenting the market growth. Additionally, the introduction of sterilizing shoes with antifungal sprays or UV light, which can help kill fungus and prevent reinfection, is expected to drive the athlete's foot market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the athlete's foot market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for athlete's foot and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the athlete's foot market in any manner.

Time Period of the Study

Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034

Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the athlete's foot market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the athlete's foot market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current athlete's foot marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug overview
Mechanism of action
Regulatory status
Clinical trial results
Drug uptake and market performance

Late-Stage Pipeline Drugs

Drug overview
Mechanism of action
Regulatory status
Clinical trial results
Drug uptake and market performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:
Market Insights

How has the athlete's foot market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the athlete's foot market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the athlete's foot market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of athlete's foot across the seven major markets?
What is the number of prevalent cases (2018-2034) of athlete's foot by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of athlete's foot by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with athlete's foot across the seven major markets?
What is the size of the athlete's foot patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of athlete's foot?
What will be the growth rate of patients across the seven major markets?

Athlete's Foot: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for athlete's foot drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the athlete's foot market?
What are the key regulatory events related to the athlete's foot market?
What is the structure of clinical trial landscape by status related to the athlete's foot market?
What is the structure of clinical trial landscape by phase related to the athlete's foot market?
What is the structure of clinical trial landscape by route of administration related to the athlete's foot market?


1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Athlete's Foot - Introduction
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 Athlete's Foot - Disease Overview
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 Patient Journey
7 Athlete's Foot - Epidemiology and Patient Population
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (​2018-2034​)
7.2.4 Epidemiology by Gender (​2018-2034​)
7.2.5 Diagnosed Cases (​2018-2034​)
7.2.6 Patient Pool/Treated Cases (​2018-2034​)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (​2018-2034​)
7.3.4 Epidemiology by Gender (​2018-2034​)
7.3.5 Diagnosed Cases (​2018-2034​)
7.3.6 Patient Pool/Treated Cases (​2018-2034​)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (​2018-2034​)
7.4.4 Epidemiology by Gender (​2018-2034​)
7.4.5 Diagnosed Cases (​2018-2034​)
7.4.6 Patient Pool/Treated Cases (​2018-2034​)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (​2018-2034​)
7.5.4 Epidemiology by Gender (​2018-2034​)
7.5.5 Diagnosed Cases (​2018-2034​)
7.5.6 Patient Pool/Treated Cases (​2018-2034​)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (​2018-2034​)
7.6.4 Epidemiology by Gender (​2018-2034​)
7.6.5 Diagnosed Cases (​2018-2034​)
7.6.6 Patient Pool/Treated Cases (​2018-2034​)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (​2018-2034​)
7.7.4 Epidemiology by Gender (​2018-2034​)
7.7.5 Diagnosed Cases (​2018-2034​)
7.7.6 Patient Pool/Treated Cases (​2018-2034​)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (​2018-2034​)
7.8.4 Epidemiology by Gender (​2018-2034​)
7.8.5 Diagnosed Cases (​2018-2034​)
7.8.6 Patient Pool/Treated Cases (​2018-2034​)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (​2018-2034​)
7.9.4 Epidemiology by Gender (​2018-2034​)
7.9.5 Diagnosed Cases (​2018-2034​)
7.9.6 Patient Pool/Treated Cases (​2018-2034​)
8 Athlete's Foot - Treatment Algorithm, Guidelines, and Medical Practices
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 Athlete's Foot - Unmet Needs
10 Athlete's Foot - Key Endpoints of Treatment
11 Athlete's Foot - Marketed Products
11.1 List of Athlete's Foot Marketed Drugs Across the Top 7 Markets
11.1.1 Ertaczo (Sertaconazole) - Bausch
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Lotrisone (clotrimazole and betamethasone dipropionate) - Merck Sharp & Dohme Corp
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Ecoza (Econazole nitrate foam) - Resilia Pharmaceuticals
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Naftin (Naftifine topical) - Sebela Pharmaceuticals
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
11.1.5 Luzu (Luliconazole) - Bausch
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Regulatory Status
11.1.5.4 Clinical Trial Results
11.1.5.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 Athlete's Foot - Pipeline Drugs
12.1 List of Athlete's Foot Pipeline Drugs Across the Top 7 Markets
12.1.1 DBI001 - DermBiont
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Dapaconazole - Biolab Sanus Farmaceutica
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 DBI-002 - DermBiont
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. Athlete's Foot - Attribute Analysis of Key Marketed and Pipeline Drugs
14. Athlete's Foot – Clinical Trial Landscape
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 Athlete's Foot - Market Scenario
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Athlete's Foot - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Athlete's Foot - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Athlete's Foot - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Athlete's Foot - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Athlete's Foot - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Athlete's Foot - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Athlete's Foot - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Athlete's Foot - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Athlete's Foot - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Athlete's Foot - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Athlete's Foot - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Athlete's Foot - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Athlete's Foot - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Athlete's Foot - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Athlete's Foot - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Athlete's Foot - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Athlete's Foot - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Athlete's Foot - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Athlete's Foot - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Athlete's Foot - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Athlete's Foot - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Athlete's Foot - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Athlete's Foot - Access and Reimbursement Overview
16 Athlete's Foot - Recent Events and Inputs From Key Opinion Leaders
17 Athlete's Foot Market - SWOT Analysis
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 Athlete's Foot Market – Strategic Recommendations
19 Appendix

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings